Intense Pulsed Light in Meibomian Gland Dysfunctions (LACRYSTIM)

Centre Hospitalier Universitaire de Saint Etienne

Status: Completed

Conditions: Meibomian Gland Dysfunction; Dry Eye Syndromes

Treatments: Device: intense pulsed light (usual practice)

Study type: Observational

Funder types: Other; Industry

Identifiers

NCT04147962

IRBN672019/CHUSTE

Details and patient eligibility

About

Dry eye disease (DED) is an extremely common disease whose meibomian gland dysfunction is the main etiology.

Polychromatic intense pulsed light (IPL) is a promising new therapeutic alternative but few clinical data have been published.

A new IPL device has recently been marketed: LACRYSTIM (QUANTEL, France). The investigators have been using it in our clinical practice since June 2019.

The investigators present a retrospective study on our first clinical results.

Enrollment: 45 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients with Dry eye disease with meibomian gland dysfunction, preferentially mild to moderate, and having benefited from intense pulsed light treatment.
• patient affiliated with a social security organization

Exclusion criteria

• patient with incomplete follow-up

Trial design

45 participants in 1 patient group

Patients with dry eye disease with meibomian gland dysfunction

Description:

Collected data from patient records for consultations Day 0, Day 15 and Day 45 (3 treatment sessions) and Months 3, Months 6 (follow-up consultations). - parameters used for each treatment session: duration of treatment session and intensity of intense pulsed light

Treatment:

Device: intense pulsed light (usual practice)